KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Income from Continuing Operations data on record, last reported at 268065000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 1769.22% year-over-year to 268065000.0; the TTM value through Dec 2025 reached 367024000.0, up 1999.08%, while the annual FY2025 figure was 367024000.0, 1999.08% up from the prior year.
  • Income from Continuing Operations reached 268065000.0 in Q4 2025 per RIGL's latest filing, up from 27900000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 268065000.0 in Q4 2025 and bottomed at 27445000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 14146800.0, with a median of 3361000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: tumbled 169.53% in 2022, then soared 5887.67% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 22601000.0 in 2021, then soared by 106.2% to 1401000.0 in 2022, then plummeted by 47.39% to 737000.0 in 2023, then soared by 1845.86% to 14341000.0 in 2024, then surged by 1769.22% to 268065000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 268065000.0 in Q4 2025, 27900000.0 in Q3 2025, and 59613000.0 in Q2 2025.